Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer

Monocentric, Prospective Study Assessing the Feasibility to Use Resting Energy Expenditure by Indirect Calorimetry as Prognostic Marker of Tumoral Response to 1st Line Chemotherapy in Patients Suffering From Metastatic Pancreatic Cancer

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02921646

Acronym

EnergiePancrea

Enrollment

Registered

2016-10-03

Start date

2017-07-10

Completion date

2019-07-10

Last updated

2020-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Pancreatic Cancer

Keywords

energetic expenditure

Brief summary

The purpose of this study is to determine whether evolution of resting energetic expenditure is a predictive marker of tumoral response for patients suffering from metastatic pancreatic cancer and treated with 1st line of chemotherapy.

Interventions

OTHERMeasure of resting energetic expenditure

measure of resting energetic expenditure

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pancreatic metastatic cancer * Patient older than 18 years * Initiation of a first line of chemotherapy by Folfirinox, or Gemcitabine or in combination with Nab-Paclitaxel. * At least one measurable target lesion * Patient signed consent for Energie-Pancreas study participation

Exclusion criteria

* Other concomitant cancer * Major general status alteration ( Performance status = 3 or 4 at inclusion) * Concomitant diseases explaining an altered general status or having an impact on energetic expenditure (i.e.chronic or severe infection, severe cardiac insufficiency, severe respiratory insufficiency, chronic inflammatory disease, recent surgery (\< 1 month), ongoing Healing, hyperthyroidism. * Smoker * Patient deprived of his liberty, under guardianship, curator. * Pregnant patient or breastfeeding * Claustrophobic patient

Design outcomes

Primary

Measure	Time frame	Description
Resting energetic expenditure measurement by indirect calorimetry	4 months	Unit measure : calorie per day

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026